Gilead和全球基金以成本向低收入国家供应新的艾滋病毒药物Lenacapavir。 Gilead and Global Fund to supply new HIV drug, lenacapavir, to low-income countries at cost.

Gilead Science和全球基金已同意向低收入国家供应新的艾滋病毒预防药物Lenacapavir。 Gilead Sciences and the Global Fund have agreed to supply the new HIV prevention drug, lenacapavir, to low-income countries. 经美国批准,这种每年两次的注射可以将艾滋病毒传播风险降低99.9%以上。 Approved in the U.S., this twice-yearly injection can reduce HIV transmission risk by over 99.9%. Gilead将在三年内以成本向多达200万人提供该药物。 Gilead will provide the drug at cost to reach up to 2 million people over three years. 世界卫生组织正在对此进行审查,第一批货物预计将在今年年底前运抵非洲。 The World Health Organization is reviewing it, and the first shipments are expected to reach Africa by the end of the year.